openPR Logo
Press release

RNA Therapy Improves Vision in Child Blindness, hear more about recent developments in RNA Therapy at RNA Therapeutics 2019

01-02-2019 02:29 PM CET | Health & Medicine

Press release from: SMi Group

RNA Therapy Improves Vision in Child Blindness, hear more about

SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.

Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved the vision of LCA-affected children in a small clinical study.*

The field of RNA therapeutics has seen dramatic, positive developments in the last few years, moving towards the path of treatment for multiple conditions where the current standard of therapy is failing.

The study, published in Nature Medicine, found one patient improve from only being able to differentiate light or dark, to reading letters on an eye chart two months after the first injection.

Antisense oligonucleotides, used in the above study, were found to influence RNA processing and modulate protein expression over 20 years ago and much progress has been made translating these agents into a clinical setting.

This year’s RNA Therapeutics Conference (http://www.therapeutics-rna.com/openpr), returning to London, UK on 20th – 21st February for its 10th year running, is set to deliver in-depth presentations from senior, internationally renowned industry experts including Exicure, Roche, MHRA, Dicerna Pharmaceuticals, Accanis Biotech, Ethris, Alnylam, and many more.

Focused presentations on oligonucleotide therapies, opportunities and challenges in drug developments, and securing oligonucleotide supply include:

“Advances in Targeted Delivery of Anti-Sense Oligonucleotide Therapeutics to Pancreatic SS-Cells for Regenerative Approaches in Type 2 Diabetes”, presented by Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca.

“Delivering Therapeutic Oligonucleotides across Biobarriers: Opportunities and Challenges in Drug Development”, presented by Ekkehard Leberer, Senior Director, Sanofi-Aventis Deutschland GmbH.
“Planning for Oligonucleotide Supply: Personalized Medicine to Large Scale Markets”, presented by Hans Kistemaker, Associate Director, ProQR.
Visit the website for more information and to download the latest brochure with the full agenda and speaker line-up, as well as other exclusive content at: http://www.therapeutics-rna.com/openpr

10th Annual RNA Therapeutics Conference
20th – 21st February 2019
London, UK

*Nature.com

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

SMi Group Ltd, India House, 45 Curlew Street, London, SE1 2ND
Maria Mandic
mmandic@smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release RNA Therapy Improves Vision in Child Blindness, hear more about recent developments in RNA Therapy at RNA Therapeutics 2019 here

News-ID: 1466387 • Views: 508

More Releases from SMi Group

Senior experts to deliver the latest insight on Military UUVs at Unmanned Mariti …
SMi reports: Unmanned Underwater Vehicles (UUVs) is a key topic of discussion at the 4th Annual Unmanned Maritime Systems Conference in London, this November Unmanned underwater vehicles already play a significant role in naval warfare. In recent years, several developmental systems have reached levels of maturity at which they can be used in direct support of combat operations. The underwater realm is the most difficult because of the limitations of underwater
British Army and UK MoD to Provide Comprehensive Briefings at Future Armoured Ve …
Future Armoured Vehicles Survivability 2020, taking place in London this November, will provide a platform for programme and platform managers, capability directors, military commanders, senior engineers and chief scientists to discuss what is being done to protect armoured vehicles and their personnel. The event will feature presentations from speakers from across the globe, with confirmed representation from 9 nations, including the UK, the US, Australia, Germany, Israel, Turkey, Norway, Sweden and
Military PNT 2020 Will Now Take Place as a Virtual Conference
With the continued uncertainty surrounding large gatherings in the UK, SMi Group have made the decision to turn the Military PNT Conference on the 19th – 20th October 2020 into a fully interactive virtual meeting. All attendance by military and government will be free of charge and other delegates can join for only £499. Register online at http://www.militarypnt.com/openpr10 This means the conference will go ahead as planned, with the full support
Energy from Waste 2020 To Discuss the Role of EfW in Reaching Net Zero
The Energy from Waste industry is striving to achieve targets set by the EU, with many countries aiming to be one of the world's first circle economies. This December, the progress of residual waste will be discussed in depth at the 13th annual Energy from Waste conference, which will take place in London on 1st – 2nd December 2020 to explore how market leaders are paving the way for a low

All 5 Releases


More Releases for RNA

Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
Topics Presented this February 2018 at RNA Therapeutics
SMi’s RNA Therapeutics will be bringing a global presence from MHRA, The RNA Institute, MiNA Therapeutics, AstraZeneca R&D, GSK, Sanofi, CureVac and more. With an agenda full of exciting and new approaches, examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches and patenting RNA Therapeutics. www.therapeutics-rna.com/opr Spotlight: Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis? Have questions answered during
RNA Analysis Market worth 3.62 billion USD by 2021
RNA Analysis Market size was around USD 1.89 billion in 2016. It is expected to grow at a CAGR of 13.9% to reach USD 3.62 billion by 2021. The market is mainly driven by the increasing technological advancements, increasing investment in research and development by biotechnology and pharmaceutical companies, rising government and private funding, and growing preference for personalized medicines. However, lack of skilled professionals in the transcriptomics field and lack
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and